Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luigi Spadafora

Showing results (51-60 of 84) with videos related to

Pageof 9
Sort By:
European Journal of Preventive Cardiology|February 21, 2024
Cardiovascular disease as part of Long COVID: a systematic reviewVasiliki Tsampasian, Maria Bäck, Marco Bernardi, et al.
Journal of Clinical Medicine|June 19, 2024
Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older AdultsMarco Bernardi, Luigi Spadafora, Silvia Andaloro, et al.
International Journal of Molecular Sciences|February 13, 2025
Combining Colchicine and Antiplatelet Therapy to Tackle Atherothrombosis: A Paradigm in Transition?Salvatore Giordano, Marina Camera, Marta Brambilla, et al.
Panminerva Medica|June 19, 2023
Appraising features and outlook of women and men discharged after an acute coronary syndrome: evidence from the 23,700-patient PRAISE International RegistryLuigi Spadafora, Tanya Mohammadi, Marco Bernardi, et al.
Minerva Cardiology and Angiology|November 16, 2023
Blockchain technology in Cardiovascular Medicine: a glance to the future? Results from a social media survey and future perspectivesLuigi Spadafora, Gian L Comandini, Salvatore Giordano, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 10, 2024
Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex PatientsLuigi Spadafora, Marco Bernardi, Gianmarco Sarto, et al.
Journal of Cardiovascular Pharmacology|February 23, 2026
Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failureGianmarco Sarto, Beatrice Simeone, Francesca Sbandi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 28, 2025
Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation AgentsLuigi Spadafora, Federico Russo, Ewelina Bukowska-Olech, et al.
Journal of the American College of Cardiology|September 2, 2025
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patientsMattia Galli, Stefano Benenati, Claudio Laudani, et al.
European Journal of Clinical Investigation|March 26, 2024
Mitophagy modulation for the treatment of cardiovascular diseasesMaurizio Forte, Luca D'Ambrosio, Gabriele G Schiattarella, et al.
Pageof 9

Showing results (51-60 of 84) with videos related to

Sort By:
Pageof 9
European Journal of Preventive Cardiology|February 21, 2024
Cardiovascular disease as part of Long COVID: a systematic reviewVasiliki Tsampasian, Maria Bäck, Marco Bernardi, et al.
Journal of Clinical Medicine|June 19, 2024
Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older AdultsMarco Bernardi, Luigi Spadafora, Silvia Andaloro, et al.
International Journal of Molecular Sciences|February 13, 2025
Combining Colchicine and Antiplatelet Therapy to Tackle Atherothrombosis: A Paradigm in Transition?Salvatore Giordano, Marina Camera, Marta Brambilla, et al.
Panminerva Medica|June 19, 2023
Appraising features and outlook of women and men discharged after an acute coronary syndrome: evidence from the 23,700-patient PRAISE International RegistryLuigi Spadafora, Tanya Mohammadi, Marco Bernardi, et al.
Minerva Cardiology and Angiology|November 16, 2023
Blockchain technology in Cardiovascular Medicine: a glance to the future? Results from a social media survey and future perspectivesLuigi Spadafora, Gian L Comandini, Salvatore Giordano, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|June 10, 2024
Towards the Fifth Pillar for the Treatment of Heart Failure with Reduced Ejection Fraction: Vericiguat in Older and Complex PatientsLuigi Spadafora, Marco Bernardi, Gianmarco Sarto, et al.
Journal of Cardiovascular Pharmacology|February 23, 2026
Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failureGianmarco Sarto, Beatrice Simeone, Francesca Sbandi, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|August 28, 2025
Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation AgentsLuigi Spadafora, Federico Russo, Ewelina Bukowska-Olech, et al.
Journal of the American College of Cardiology|September 2, 2025
Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patientsMattia Galli, Stefano Benenati, Claudio Laudani, et al.
European Journal of Clinical Investigation|March 26, 2024
Mitophagy modulation for the treatment of cardiovascular diseasesMaurizio Forte, Luca D'Ambrosio, Gabriele G Schiattarella, et al.
Pageof 9